Jan 08,2024

Qure.ai's AI-Driven Chest X-ray Solution Receives FDA Clearance for Enhanced Lung Nodule Detection

Qure.ai, a leading global innovator in medical imaging solutions, has announced its 13th FDA clearance for their AI-enabled solutions. Qure’s chest X-ray-based qXR-LN uses artificial intelligence to identify and localize lung nodules, marking another significant milestone for the organization, strengthening its standing as a pioneer in the realm of AI-powered advancements for plain film radiography and medical imaging. This also marks the 6th FDA clearance for Qure’s chest X-ray based solutions. Notably, this is the only FDA-cleared solution for detecting and localizing lung nodules utilizing computer vision to have Radiologists, Pulmonologists and ER physicians as intended users.

REGULATORY FDA

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 02,2024

SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients

SimBioSys, a TechBio company specializing in spatial biophysics and artificial intelligence (AI) for precision medicine in cancer, has entered a strategic collaboration with Mayo Clinic to develop digital precision medicine solutions for breast cancer patients. The collaboration aims to create cloud-based clinical software tools supporting the entire decision-making process for early-stage breast cancer patients, including personalized surgical planning, treatment, drug selection, and risk stratification. Mayo Clinic physicians are part of SimBioSys' clinical advisory team, contributing to the ongoing development and validation of these tools. SimBioSys is utilizing AI and data science to analyze data from the Mayo Clinic-led BEAUTY clinical trial, aiming to tailor treatment plans based on spatial biophysical insights. SimBioSys's TumorSight platform, currently under FDA review, also utilizes DCE-MRI imaging to create custom 3D digital models of tumors, aiding surgical planning with visualizations.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 04,2024

Varian and Nova Scotia Health Form First Multi-Disciplinary Oncology Partnership to Catalyze Advancements in Cancer Care

Varian, a Siemens Healthineers company, and Nova Scotia Health have established a 10-year, $175 million CAD multi-disciplinary oncology partnership aimed at advancing cancer care in Nova Scotia. The collaboration seeks to enhance patient outcomes by optimizing the cancer care pathway, from screening to survivorship. The partnership includes upgrading radiation treatment systems to Varian's Ethos radiotherapy systems with HyperSight imaging, incorporating artificial intelligence for improved precision. The collaboration aligns with the shared commitment to revolutionize cancer care and address the evolving needs of clinicians and patients.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 03,2024

New AI Tool Brings Precision Pathology for Cancer and Beyond into Quicker, Sharper Focus

Researchers at the Perelman School of Medicine, University of Pennsylvania, have developed a groundbreaking artificial intelligence (AI) tool called iStar (Inferring Super-Resolution Tissue Architecture). tool utilizes spatial transcriptomics to provide highly detailed views of individual cells and broader insights into gene activities within tissues. iStar can automatically detect critical immune formations, aiding in cancer diagnosis and treatment planning. It is particularly valuable for identifying patients likely to benefit from immunotherapy. iStar's remarkable speed, finishing analysis in nine minutes, positions it as a crucial asset for large-scale biomedical studies and 3D context applications in reconstructing spatial data from serially cut tissue slices. The researchers plan to extend iStar's applications to biobanks, contributing to a better understanding of tissue microenvironments for diagnostic and treatment advancements.

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Dec 26,2023 TOP STORY

Carrum Health, Florida Cancer Institute partner to expand breast cancer care

Carrum Health, a digital marketplace for employers to purchase bundled healthcare services, announced it has partnered with Florida Cancer Specialists & Research Institute to offer employers in Florida breast cancer care services. Carrum Health offers a value-based platform that allows self-funded employers to buy specialty care, focusing on surgical and cancer care. It provides a digital platform that gives patients access to a care specialist who guides them through the surgical process and employers a platform for navigating Carrum's network. Through the partnership, patients with non-metastatic breast cancer with employers utilizing Carrum Health can access two years of breast cancer treatment at nearly 100 FCS locations, including radiation, symptom management and chemotherapy.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Dec 22,2023

Thermal device shows feasibility in managing prostate cancer–related hot flashes

A recent study published in Prostate Cancer and Prostatic Diseases shows the feasibility of a wearable thermal device for the management of hot flashes due to treatment for prostate cancer. The device works by using a thermoelectric heat pump to provide either heating or cooling to participants’ wrists upon activation. "During treatment for prostate cancer, there are many complications we consider when we think about how to optimize survivorship. This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer,” said Alicia K. Morgans, MD, MPH, in a news release on the findings. Overall, 44 patients completed the 4-week prospective study, and 39 had retrievable device usage data for analysis. The primary outcome was device usage, indicated by hours and sessions of use per day. On average, participants used the device for 3.2 (SD, 2.5) hours per day for 7.6 (SD, 3.6) sessions per day. Among all participants, 67% reported using the device 7 days and 7 nights each week. Although the device could provide heating and cooling, all participants used the device exclusively for cooling. Across all secondary measures analyzed, the investigators observed statistically significant changes from baseline to week 4. Regarding patient reported outcome measures, most participants (69%) indicated that the device was effective in helping them manage their hot flashes, and 77% reported being somewhat to very satisfied with the device.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Jan 04,2024 TOP STORY

Aptar Digital Health and Gerresheimer to Develop Integrated Cancer Therapy Solution

Aptar Digital Health announced a new collaboration with Gerresheimer, an innovative systems and solutions provider and global partner to the pharma, biotech and cosmetics industries, to develop a tailored solution to support patients and health care professionals in cancer therapy management. By connecting Aptar Digital Health’s proprietary SaMD platform with Gx SensAir, Gerresheimer’s on-body device for the subcutaneous delivery of large biologics molecules, this integrated solution is intended to improve overall treatment adherence and clinical outcomes. More specifically, it aims to make remote patient monitoring easier, and facilitate the onboarding of patients to new therapies, helping them to better manage adverse effects. For pharmaceutical companies, this collaboration is an opportunity to offer a more patient-centric solution, and tackle potential challenges, such as treatment interruptions or discontinuations related to administration issues or adverse effects. This solution will also support the transition from intravenous to subcutaneous administration of oncology drugs. This integrated solution will first be designed for targeted anti-cancer therapies such as PD-1/PDL-1, CTLA-4, with the potential to expand to all therapies delivered subcutaneously.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Nov 28,2023

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Real-world data (RWD) is being increasingly used to support clinical and regulatory decisions where utilization of clinical trial data is difficult or impractical. With this expanded utilization comes a need to ensure RWD is of sufficient quality and completeness to adequately answer relevant research questions. Given the importance of overall survival (OS) for oncology research, treatment and care, complete and accurate real-world mortality data capture is of critical importance. This study sought to validate and benchmark a composite real-world mortality variable, using the COTA real-world database, a de-identified database derived from the electronic health records (EHRs) of partnered healthcare providers in the United States, against the gold standard data source from the National Death Index (NDI). The final study population included 21,567 patients across 7 cancer types. Within the overall study population, validation analysis comparing the real-world composite mortality variable to the NDI demonstrated high sensitivity (87.8) and specificity (95.7). Date concordance between the real-world composite mortality variable and NDI dates of death was high. In the study population (N=21,567), exact date concordance was observed in 88.0% of patients. These findings are critical to ensure the reliability of results generated using RWD, and further establish the use of a composite real-world mortality variable as best practice.

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 19,2023 TOP STORY

Owkin and MSD join forces on AI-powered digital pathology

Pharma group MSD has joined forces with Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for immunotherapies. The focus of the alliance is the development of diagnostic digital pathology tools that can help pathologists and oncologists assess microsatellite instability-high (MSI-H) tumours, which indicate a defect in a cell’s ability to correct mistakes that occur when DNA is replicated. These genetically disrupted tumours tend to respond well to PD-1/PD-L1 inhibitor therapies, like MSD’s Keytruda (pembrolizumab). The aim is to come up with tools that can pre-screen patients with four tumour types for the MSI-H biomarker, namely endometrial, gastric, small intestinal, and biliary cancers. MSD – known as Merck & Co in North America – will be responsible for developing and commercialising the digital tools, initially in the EU.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Dec 14,2023 TOP STORY

PathAI Introduces TumorDetect, an AI Solution to Automate Tumor Assessment and Case Prioritization for Anatomic Pathology Labs

PathAI announced TumorDetect on AISight, PathAI’s digital pathology image management system. TumorDetect is an AI-powered feature of AISight which automates the assessment and quantification of tumor across diverse tissue types. This product transforms pathology workflows by enabling case prioritization based on tumor content, helping pathologists to expedite case review, accelerate ordering of additional tests, and improving overall case turnaround time. PathAI will be expanding this pilot across its network of 50+ laboratory and early access partners across diverse tumor types globally. TumorDetect’s assessment and prioritization criteria are also customizable, allowing pathologists to set personalized tumor content thresholds in line with their unique preferences and requirements. In addition to tumor cell quantification, TumorDetect also generates overlay visualizations highlighting hotspots of possible tumor on whole slide images (WSI).

PRODUCT

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY